Not finding it? Sign in to also search OpenAlex live.
-
Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry2025 Journal of the American College of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Margrét Leósdóttir, Jessica R. Schubert, Julia Brandts, Stefan Gustafsson, Thomas Cars, Johan Sundström, +3 more
61citations -
Usage of bempedoic acid and/or its fixed-dose combination with ezetimibe in Belgian patients with dyslipidaemia: Baseline characteristics and 8-week follow-up data from the MILOS study
Thomas Vanassche, Ioanna Gouni‐Berthold, J. Wouter Jukema, Jeanine E. Roeters van Lennep, Kausik Kumar Ray, Konstantinos C. Koskinas, +7 more
3citations -
Real world insights from the United Kingdom on 8-week effectiveness of bempedoic acid and/or its fixed-dose combination with ezetimibe in patients with dyslipidaemia
Kausik Kumar Ray, Ioanna Gouni‐Berthold, J. Wouter Jukema, Jeanine E. Roeters van Lennep, Konstantinos C. Koskinas, Thomas M. Stulnig, +7 more
1citations -
Obicetrapib alone and in combination with ezetimibe reduces non-HDL-cholesterol by enhanced LDL-receptor-mediated VLDL clearance and increased net fecal sterol excretion in apoe*3-leiden.cetp mice
José A. Inia, Nanda Keijzer, Nicole Worms, Anita van Nieuwkoop, Marc Ditmarsch, J. Wouter Jukema, +5 more
1citations -
Obicetrapib Alone and in Combination with Ezetimibe Reduces Atherosclerotic Lesion Prevalence, Size and Severity in ApoE*3-Leiden.CETP Mice2024 American Heart Journal article Medicine Lipoproteins and Cardiovascular Health cited by 1 patent
José A. Inia, Nanda Keijzer, Nicole Worms, Anita van Nieuwkoop, Marc Ditmarsch, J Wouter Jukema, +2 more
0citations -
Obicetrapib Alone and in Combination with Ezetimibe Reduces Non-HDL-Cholesterol by Enhanced LDL-Receptor-Mediated VLDL Clearance and Increased Net Fecal Sterol Excretion in ApoE*3-Leiden.CETP Mice
José A. Inia, Nanda Keijzer, Nicole Worms, Anita van Nieuwkoop, Marc Ditmarsch, J. Wouter Jukema, +3 more
0citations -
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab2022 European Journal of Preventive Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Ulf Landmesser, Jennifer McGinniss, Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, +10 more
17citations -
Efficacy and safety of alirocumab in patients with established atherosclerotic vascular disease before the first cardiovascular event: Pooled analysis of phase 3 ODYSSEY studies2025 Journal of clinical lipidology article Medicine Lipoproteins and Cardiovascular Health Open access
Manuel Castro Cabezas, Mattéa Orsini, Lâle Tokgözoğlu, Nikolaus Marx, José Tuñón, Michal Vrablı́k, +3 more
2citations -
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study2020 European Journal of Preventive Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Kausik Kumar Ray, Bart Molemans, W. Marieke Schoonen, Periklis P. Giovas, Sarah L Bray, Gaia Kiru, +23 more
818citations -
Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study2023 The Lancet Regional Health - Europe article Medicine Lipoproteins and Cardiovascular Health Open access
Julia Brandts, Sarah L Bray, Guillermo Villa, Alberico Luigi Catapano, Neil R Poulter, Antonio J. Vallejo‐Vaz, +1 more
45citations -
L ow‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German–Austrian diabetes registry2023 Diabetes Obesity and Metabolism article Medicine Lipoproteins and Cardiovascular Health Open access
Julia Brandts, Sascha René Tittel, Peter Bramlage, Thomas Danne, Johanna Maria Brix, Stefan Zimny, +3 more
30citations -
Association between high-intensity lipid-lowering therapy and atherosclerotic plaque content changes assed by iMAP-IVUS and near-infrared spectroscopy in patients with premature atherosclerosis
Maris Lapsovs, Kārlis Trušinskis, Baiba Kokina, Evija Knoka, Mairita Karantajere, Laima Caunīte, +2 more
0citations -
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab2020 European Journal of Preventive Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Antonio J. Vallejo‐Vaz, Lawrence A. Leiter, Stefano Del Prato, Marja‐Riitta Taskinen, Dirk Müller‐Wieland, Maja Bujas‐Bobanovic, +4 more
15citations